Sara M Tinsley
Overview
Explore the profile of Sara M Tinsley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
39
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Park M, Whelan C, Ahmed S, Boeringer T, Brown J, Crowder S, et al.
Cancers (Basel)
. 2024 Jul;
16(13).
PMID: 39001427
For many patients, the cancer continuum includes a syndrome known as cancer-associated cachexia (CAC), which encompasses the unintended loss of body weight and muscle mass, and is often associated with...
2.
Ball S, Aguirre L, Jain A, Al Ali N, Tinsley S, Chan O, et al.
Leuk Res
. 2022 Dec;
124:106999.
PMID: 36542963
EZH2 mutations in myeloid neoplasms are loss of function type, and have been linked to poor overall survival (OS) in patients with myelodysplastic syndrome (MDS). However, the specific determinants of...
3.
Tinsley S, Grande C, Olson K, Plato L, Jacobs I
J Adv Pract Oncol
. 2019 Jun;
9(7):699-716.
PMID: 31249718
Biosimilars are biologic products that are highly similar, but not identical, to a licensed reference (or "originator") biologic product. These agents have the potential to provide efficiencies and improve access...
4.
Tinsley S, Hoehner-Cooper C
J Infus Nurs
. 2018 Apr;
41(3):171-175.
PMID: 29659464
Iron overload is a concern for patients who require chronic transfusions as a result of inherited or acquired anemias, including sickle cell disease, thalassemia, and myelodysplastic syndromes. Iron chelation therapy...
5.
Tinsley S, Sutton S, Thapa R, Lancet J, McMillan S
Clin Lymphoma Myeloma Leuk
. 2017 Aug;
17S:S75-S79.
PMID: 28760305
Background: In the present exploratory, observational study, we compared the effect of intensive versus nonintensive treatment on quality of life for patients aged ≥ 60 years diagnosed with acute myeloid...
6.
Tinsley S, Kurtin S, Ridgeway J
Clin Lymphoma Myeloma Leuk
. 2015 Aug;
15 Suppl:S64-9.
PMID: 26297281
Lenalidomide (LEN) is an immunomodulatory drug with US Food and Drug Administration approval for use in myelodysplastic syndromes (MDS), multiple myeloma (MM), and mantle cell lymphoma (MCL). The toxicity profile...
7.
Safety profiles of second-line tyrosine kinase inhibitors in patients with chronic myeloid leukaemia
Tinsley S
J Clin Nurs
. 2010 Mar;
19(9-10):1207-18.
PMID: 20345830
Aims And Objectives: To review the use of second-line tyrosine kinase inhibitors in patients with chronic myeloid leukaemia (CML) and provide recommendations for managing adverse events (AEs) to maximise patient...